Syncom Formulations' Q1 Profit Soars: The Secret Revealed

Syncom Formulations (India) Limited announces robust Q1 FY2026-27 results, with income up 8% and profit after tax soaring 58%. Discover how their ethical, prescription-led model and quality manufacturing drive sustainable growth and strong financial performance.